Sandra Sanders-van Wijk

Post doc

Dr Sandra Sanders-van Wijk graduated cum laude at the WereDi scholengemeenschap Valkenswaard in 2003 (Gymnasium/VWO). She received her master’s diploma Medicine (Geneeskunde) at Maastricht University in 2010 and obtained her doctorate/PhD thesis in 2015, entitled ‘Biomarkers in heart failure: towards individualized therapy’, focussing on clinical heart failure (HF) and biomarker research (promotor Prof. H.P. Brunner-La Rocca). She started her clinical training in cardiology (cardioloog in opleiding) in 2014 (expected end date January 2021). She won the Netherlands Heart Institute fellowship in 2018; a grant to do a 6 month post-doc abroad, spend at Northwestern University/Memorial hospital with Prof. S.J. Shah studying biomarkers in HFpEF (November 2018-April 2019). Published >20 peer-reviewed articles and 2 editorials. She has presented her research results at >10 national and international scientific conferences and was awarded ‘best speaker’ in the HF session of the Dutch cardiology conference (NVVC) in 2012. She is a reviewer for e.g. European Journal of Heart Failure.

Her current research focus is clinical research in heart failure in general and HFpEF in particular. Biomarkers (mainly circulating biomarkers) remain an area of interest and are employed to unravel disease processes, to better diagnose and to target therapy, using different holistic system biology approaches such as network & pathway analyses, mediation analysis, cluster analysis etc. Alongside biomarkers, her research focusses on general clinical and pathophysiological issues in HF, such as integrated care, eHealth applications, iron deficiency, influence of comorbidities in HF and for HFpEF specifically the focus is on inflammation and endothelial dysfunction. She has particular interest and knowledge of advanced statistical modelling/bioinformatics and database building/management (R/SPSS/Microsoft access/Cytoscape/Metascape etc).


Department of Cardiology
P. Debyelaan 25, 6229 HX Maastricht 
PO Box 5800, 6202 AZ Maastricht
T: +31(0)630 412 408

  • 2020
    • Henkens, M. T. H. M., Remmelzwaal, S., Robinson, E. L., van Ballegooijen, A. J., Aizpurua, A. B., Verdonschot, J. A. J., Raafs, A. G., Weerts, J., Hazebroek, M. R., Wijk, S. S., Handoko, M. L., den Ruijter, H. M., Lam, C. S. P., de Boer, R. A., Paulus, W. J., van Empel, V. P. M., Vos, R., Rocca, H-P. B-L., Beulens, J. W. J., & Heymans, S. R. B. (2020). Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European journal of heart failure, 22(9), 1586-1597.
    • Barutaut, M., Fournier, P., Peacock, W. F., Evaristi, M. F., Caubere, C., Turkieh, A., Desmoulin, F., Eurlings, L. W. M., van Wijk, S., Brunner-La Rocca, H-P., Butler, J., Koukoui, F., Dambrin, C., Mazeres, S., Le Page, S., Delmas, C., Galinier, M., Jung, C., Smih, F., & Rouet, P. (2020). Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. International Journal of Cardiology, 300, 245-251.
  • 2019
    • Tromp, J., Hage, C., Ouwerkerk, W., Sanders-van Wijk, S., Svedlund, S., Saraste, A., Ljung Faxen, U., Lagerstrom Fermer, M., Gan, L., Lund, L. H., Shah, S. J., & Lam, C. S. P. (2019). Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation, 140(16), 1359-1361.
    • Simonavicius, J., Van-Wijk, S. S., Rickenbacher, P., Maeder, M. T., Pfister, O., Kaufmann, B. A., Pfisterer, M., Celutkiene, J., Puronaite, R., Knackstedt, C., van Empel, V., & Brunner-La Rocca, H-P. (2019). Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial. American Journal of Medicine, 132(9), E679-E692.
    • Brunner-La Rocca, H., & Sanders - van Wijk, S. (2019). Natriuretic Peptides in Chronic Heart Failure. Cardiac Failure Review, 5(1), 44-49.
  • 2018
    • Bocchi, E. A., da Cruz, F. D. D., Brandao, S. M., Issa, V., Ayub-Ferreira, S. M., la Rocca, H-P. B., & van Wijk, S. S. (2018). Cost-Effectiveness Benefits of a Disease Management Program: The REMADHE Trial Results. Journal of Cardiac Failure, 24(10), 627-637.
  • 2017
    • Davarzani, N., van Wijk, S., Karel, J., Maeder, M. T., Leibundgut, G., Gutmann, M., Pfisterer, M. E., Rickenbacher, P., Peeters, R., & Brunner-La Rocca, H. (2017). N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF. Journal of Cardiac Failure, 23(5), 382-389.
  • 2015
    • Berry, M., Galinier, M., Delmas, C., Fournier, P., Desmoulin, F., Turkieh, A., Mischak, H., Mullen, W., Barutaut, M., Eurlings, L. W., Van Wijk, S., Rocca, H-P. B-L., Caubere, C., Butler, J., Roncalli, J., Evaristi, M. F., Cohen-Solal, A., Seronde, M-F., Escamilla, R., ... Rouet, P. (2015). Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure. International Journal of Cardiology - Metabolic & Endocrine , 6, 5-12.
  • 2010
    • Eurlings, L. W. M., van Pol, P. E. J., Kok, W. E., van Wijk, S., Lodewijks-van der Bolt, C. L. B., Balk, A. H. M. M., Lok, D. J. A., Crijns, H. J. G. M., van Kraaij, D. J. W., de Jonge, N., Meeder, J. G., Prins, M., & Pinto, Y. M. (2010). Management of Chronic Heart Failure Guided by Individual N-Terminal Pro-B-Type Natriuretic Peptide Targets Results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) Study. Journal of the American College of Cardiology, 56(25), 2090-2100.